Dyax News

Aug 28, 2008 - Dyax Corp. , a developer of novel biotherapeutics for unmet medical needs, announced today that Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax, will present at the Thomas ...

Rare diseases may not be profitable for companies to treat, but people still need recovery options and smaller biotechs are in the best position to provide them.

Dyax Announces DX-88 For Hereditary Angioedema Meets Primary And Secondary Endpoints In Phase 3 Trial ) Main Category: Cardiovascular / Cardiology Also Included In: Clinical Trials / Drug Trials Article Date: ...

Dyax Corp.'s experimental drug DX-88 met its goal of reducing symptoms of hereditary angioedema in a second Phase III trial, sending shares of the firm up 15.5 percent Monday.

Dyax Corp. announced today positive topline results from its second Phase 3, placebo-controlled trial, EDEMA4, for its lead product candidate DX-88 for hereditary angioedema .

Dyax Corp. announced today positive topline results from its second Phase 3, placebo-controlled trial, EDEMA4, for its lead product candidate DX-88 for hereditary angioedema .

Drug stocks rose slightly in early action Monday as shares of Dyax Corp. jumped up on news that it plans to file for U.S. regulatory approval of its drug candidate DX-88 during the first part of the fourth ...

Biotherapeutics company Dyax Corp. reports it has named George Migausky as executive vice president and chief financial officer, who will be replacing Steve S. Galliker , who is retiring.

Dyax Corp. has secured a $50 million loan with equity firm Cowen Healthcare Royalty Partners LP .

Boris Buhach [ph] - " Kevin Capital [ph] Presentation Operator Good morning, and welcome ladies and gentlemen to Dyax Corporation's Second Quarter 2008 Earnings call.

On Tuesday, it made the move with the acquisition of orphan-drug developer Lev Pharmaceuticals for up to $618 million.

Dyax Corp. announced ahead of today's opening it had entered an exclusive negotiation period with Dompe Farmaceutici S.p.A. for a European license to DX-88 in angioedema indications.

The United States Court of Appeals for the Eleventh Circuit has affirmed a $176 million judgment in a federal civil racketeering case against Luis Alvarez Renta, a - [ more ] [ more ] HUNTERSVILLE, N.C.-- ...

“I am delighted to execute this licence agreement with Dyax”

Novozymes has announced that it has granted non-exclusive licenses for its proprietary albumin fusion technology, albufuse , and yeast-based expression platform to Dyax Corp. via Med Ad News

Dyax Corp. Company Profile - View Dyax Corp. Company Information Use of, registration on, this site constitutes acceptance of our User Agreement . via Boston Business Journal

“We remain on course for year-end market approval.”

In what the company called part of a "multistep commercialization strategy" for DX-88, Dyax Corp. via BioWorld

“Throughout the year, we made tremendous progress in positioning Dyax for the next stage of transition and growth, which will include delivery of DX-88 partnerships, clinical trial data announcements and market approval for the HAE indication”

Feb 27, 2008 - Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2007. via Med Ad News

“These strategic agreements validate Dyax's capabilities to successfully discover novel antibody drug candidates utilizing our proprietary phage display technology and advance the resulting drug candidates into development”

Dyax Corp. and sanofi-aventis announced today that they have entered into agreements in which sanofi-aventis has been granted an exclusive worldwide license for the development and commercialization of the ... via BioSpace

Openwave Systems Inc. , one of the world's leading software innovators enabling revenue-generating personalized - 02/12/2008 - 12:17 AM LONDON-- --InnoPath Software, the leader in Integrated Mobile Device ... via Business Wire